BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Penn Engineering Events - ECPv6.15.18//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Penn Engineering Events
X-ORIGINAL-URL:https://seasevents.nmsdev7.com
X-WR-CALDESC:Events for Penn Engineering Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20201117T160000
DTEND;TZID=America/New_York:20201117T170000
DTSTAMP:20260407T093441
CREATED:20200709T143100Z
LAST-MODIFIED:20200709T143100Z
UID:3134-1605628800-1605632400@seasevents.nmsdev7.com
SUMMARY:Immunology/BE Seminar: “Engineering Next-Generation CAR-T Cells for Cancer Immunotherapy” (Yvonne Chen)
DESCRIPTION:This event is part of the Penn Institute for Immunology Colloquium seminar series and is co-hosted by the Department of Bioengineering. This virtual event will be held on Bluejeans. \nAttend the live seminar via this link. Or download the Bluejeans app and and enter ID: wxbzgity \nContact ifiadmin@pennmedicine.upenn.edu with any questions. \nThe adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has demonstrated clinical efficacy in the treatment of advanced cancers\, with anti-CD19 CAR-T cells achieving up to 90% complete remission among patients with relapsed B-cell malignancies. However\, challenges such as antigen escape and immunosuppression limit the long-term efficacy of adoptive T-cell therapy. Here\, I will discuss the development of next-generation T cells that can target multiple cancer antigens and resist immunosuppression\, thereby increasing the robustness of therapeutic T cells against tumor defense mechanisms. Specifically\, I will discuss the development of multi-input receptors and T cells that can interrogate intracellular antigens. I will also discuss the engineering of T cells that can effectively convert TGF-beta from a potent immunosuppressive cytokine into a T-cell stimulant. This presentation will highlight the potential of synthetic biology in generating novel mammalian cell systems with multifunctional outputs for therapeutic applications.
URL:https://seasevents.nmsdev7.com/event/immunology-be-seminar-engineering-next-generation-car-t-cells-for-cancer-immunotherapy/
CATEGORIES:Seminar,Colloquium
ORGANIZER;CN="Bioengineering":MAILTO:be@seas.upenn.edu
END:VEVENT
END:VCALENDAR